Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) FCF Margin (2020 - 2025)

Lyell Immunopharma's FCF Margin history spans 6 years, with the latest figure at 187753.33% for Q3 2025.

  • For Q3 2025, FCF Margin fell 8568275.0% year-over-year to 187753.33%; the TTM value through Sep 2025 reached 402770.73%, down 15963105.0%, while the annual FY2024 figure was 266455.74%, 14051497.0% down from the prior year.
  • FCF Margin for Q3 2025 was 187753.33% at Lyell Immunopharma, up from 433962.5% in the prior quarter.
  • Across five years, FCF Margin topped out at 126.03% in Q4 2022 and bottomed at 1407866.67% in Q1 2024.
  • The 5-year median for FCF Margin is 148496.3% (2023), against an average of 269279.06%.
  • The largest annual shift saw FCF Margin surged 64057600bps in 2023 before it plummeted -133441282bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 1540.79% in 2021, then soared by 92bps to 126.03% in 2022, then crashed by -231857bps to 292330.77% in 2023, then plummeted by -47bps to 430572.73% in 2024, then soared by 56bps to 187753.33% in 2025.
  • Per Business Quant, the three most recent readings for LYEL's FCF Margin are 187753.33% (Q3 2025), 433962.5% (Q2 2025), and 784185.71% (Q1 2025).